CoChat

Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes.

Open access
Parker, J C, McPherson, R K, Andrews, K M, Levy, C B, Dubins, J S, Chin, J E, Perry, P V, Hulin, B, Perry, D A, Inagaki, T, Dekker, K A, Tachikawa, K, Sugie, Y, Treadway, J L · 2000 · Diabetes
Cited by 65

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Peptidic glucagon antagonists have been shown to lower blood glucose levels in diabetic models (1-3), but attempts to identify small molecular weight glucagon receptor-binding antagonists have met with little success. Skyrin, a fungal bisanthroquinone, exhibits functional glucagon antagonism by uncoupling the glucagon receptor from adenylate cyclase activation in rat liver membranes (1). We have examined the effects of skyrin on cells transfected with the human glucagon receptor and on isolated rat and human hepatocytes. The skyrin used was isolated from Talaromyces wortmanni American Type Culture Collection 10517. In rat hepatocytes, skyrin (30 micromol/l) inhibited glucagon-stimulated cAMP production (53%) and glucose output (IC50 56 micromol/l). There was no detectable effect on epinephrine or glucagon-like peptide 1 (GLP-1) stimulation of these parameters, which demonstrates skyrin's selective activity. Skyrin was also evaluated in primary cultures of human hepatocytes. Unlike cell lines, which are largely unresponsive to glucagon, primary human hepatocytes exhibited glucagon-dependent cAMP production for 14 days in culture (EC50 10 nmol/l). Skyrin (10 micromol/l) markedly reduced glucagon-stimulated cAMP production (55%) and glycogenolysis (27%) in human hepatocytes. The inhibition of glucagon stimulation was a specific property displayed by skyrin and oxyskyrin but not shared by other bisanthroquinones. Skyrin is the first small molecular weight nonpeptidic agent demonstrated to interfere with the coupling of glucagon to adenylate cyclase independent of binding to the glucagon receptor. The data presented in this study indicate that functional uncoupling of the human glucagon receptor from cAMP production results in metabolic effects that could reduce hepatocyte glucose production and hence alleviate diabetic hyperglycemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.49.12.2079

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 65

Metadata

Authors
Parker, J. C., McPherson, R. K., Andrews, K. M., Levy, C. B., Dubins, J. S., Chin, J. E., Perry, P. V., Hulin, B., Perry, D. A., Inagaki, T., Dekker, K. A., Tachikawa, K., Sugie, Y., & Treadway, J. L.
Venue
Diabetes
Published
2000-12-01
Volume
49
Issue
12
Pages
2079-2086
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2096420012
Cited by
65
References
2
FWCI
3.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. https://app.cochat.ai/papers/10.2337/diabetes.49.12.2079
The paper
Parker, J. C., McPherson, R. K., Andrews, K. M., Levy, C. B., Dubins, J. S., Chin, J. E., Perry, P. V., Hulin, B., Perry, D. A., Inagaki, T., Dekker, K. A., Tachikawa, K., Sugie, Y., & Treadway, J. L. (2000). Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes. https://doi.org/10.2337/diabetes.49.12.2079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.